abstract |
The invention relates to dosing regimens for the treatment of Fabry Disease in a patient. Some methods relate to the treatment of patients with Fabry disease subject to TES or not subject to TES. Some methods involve administering to the patient approximately 123 mg of migalastat free base equivalent to enhance left ventricular mass and / or improve globotriaosylceramide in podocytes. |